You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
翰森制药(03692.HK):降糖药卡格列净片获批上市
格隆汇 12-24 15:13

格隆汇12月24日丨翰森制药(03692.HK)宣布,由公司附属公司江苏豪森药业集团有限公司开发的"卡格列净片"已获中国国家药品监督管理局颁发药品注册批件。卡格列净片获批上市,成为中国首仿的钠-葡萄糖协同转运蛋白2(SGLT-2)抑制剂,用于II型糖尿病患者。

卡格列净片通过抑制肾小管对葡萄糖的重吸收而降低血液中的葡萄糖水平,从而达到治疗II型糖尿病患者的作用,该药物又因不依赖胰岛素的分泌与作用水准,对各阶段的II型糖尿病患者均有治疗效果。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account